| Literature DB >> 30327780 |
Amro Abdelazez1,2, Heba Abdelmotaal3,4, Smith Etareri Evivie1,5, Sherif Melak6,7, Fang-Fang Jia1, Mir Hassan Khoso4, Zong-Tao Zhu1, Lu-Ji Zhang1, Rokayya Sami8, Xiang-Chen Meng1.
Abstract
Diabetes has become the third most serious threat to human health, after cancer and cardiovascular disease. Notably, Lactobacillus brevis is the most common species of LAB that produces γ-aminobutyric acid (GABA). The aim of this study is to clarify the effect of time, strain types, antibiotic concentrations, different levels of pH, and intestinal juices in aerobic or anaerobic conditions and the effect of interactions between these factors on the potential properties of KLDS 1.0727 and KLDS 1.0373, furthermore, antagonistic activity against foodborne pathogens. Moreover, another aim is to study the capability of KLDS 1.0727 and KLDS 1.0373 strains as gad gene carriers to express GABA that reduce the risk of type 1 diabetes in C57BL/6 mice as diabetic models. The obtained results exhibited the surprising tolerance of Lactobacillus brevis strains in vitro digestion models mimicking the conditions of the gastrointestinal tract, further, large antagonistic activity against foodborne pathogeneses. In vivo results displayed the significant effect on glucose level reduction, blood plasma, and histological assays of mice organs. As recommended, the use of Lactobacillus brevis strains should be widely shared in the market as a natural source of GABA in pharmaceutical and food applications.Entities:
Mesh:
Year: 2018 PMID: 30327780 PMCID: PMC6169223 DOI: 10.1155/2018/7356173
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Experiments design of diabetic model mice.
|
|
|
|
| |
|---|---|---|---|---|
|
| (Cont) | 250 | Daily | via gavage |
| (STZ) | 180 mg/kg | One time | subcutaneously | |
| (INS+STZ) | 100 | Daily | subcutaneously | |
| (S1) | 250 | Daily | via gavage | |
| Male C57BL/6 | (S2) | 250 | Daily | via gavage |
(Cont), control group; (STZ), streptozotocin; (INS+STZ), insulin + streptozotocin; (S1), KLDS1.0727+ streptozotocin, and (S2), KLDS1.0373+ streptozotocin.
Figure 1PCR amplification of gad gene. M: marker; 1, 2 PCR products of Lactobacillus brevis KLDS 1.0727 and 3, 4 of KLDS 1.0373.
Significance, means, and standard errors (SE) of factors affecting the growth rate of KLDS 1.0727 and KLDS 1.0373 strains.
|
|
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | High | Low | High | Low | High | Low | High | Low | High | Low | |
|
| (S1) | (S2) | (S1) | (S2) | (S1) | (S2) | (S2) | (S1) | (S2) | (S1) | (S2) | (S1) |
|
| 1.24±0.19c | 1.15±0.21 | 0.79 ±0.08c | 0.76±0.08 | 0.36±0.07d | 0.36±0.07 | 0.51±0.10b | 0.49±0.10 | 0.45±0.06c | 0.44±0.06 | 245 ±36.51d | 244.67±33.31 |
|
| 27 | 0 | 27 | 0 | 24 | 0 | 24 | 0 | 24 | 3 | - | - |
|
| 1.97±0.01c | 0.22±0.03 | 1.40±0.07c | 1.10±0.01 | 0.56±0.14c | 0.14±0.01 | 1.05±0.29c | 0.14±0.01 | 1.11±0.15c | 0.05±0.003 | - | - |
|
| - | - | 0 | 2 | 0 | 2 | 0 | 2 | Cont. | Amp. | 3 | 0 |
|
| - | - | 1.08c ±0.15 | 0.52±0.07 | 1.00±0.14c | 0.12±0.01 | 1.39±0.23c | 0.15±0.01 | 0.80 ±0.14c | 0.05±0.003 | 381.67±48.47c | 137.50±6.26 |
|
| ||||||||||||
|
| 99.99 | 99.96 | 99.98 | 99.88 | 99.99 | 72.36 | ||||||
|
| 0.67 | 2.11 | 2.64 | 6.71 | 1.83 | 30.48 | ||||||
In the six experiments, growth rate: the effect of two strains KLDS 1.0727 (S1) and KLDS 1.0373 (S2), and five levels of times 0, 3, 9, 27, and 33h on growth rate and pH; bile tolerance: the effect of two strains, five levels of times, and four levels of bile salts concentration Cont, 0.3, 1, and 2% on growth rate and pH; simulated intestinal juice (SIJ) with different pH aerobically: the effect of two strains, five levels of times 0, 3, 6, 9, and 24, and simulated intestinal juice with different four levels of pH Cont, 2, 3, and 7 on growth rate; simulated intestinal juice(SIJ) with different pH anaerobically: the effect of two strains, five levels of times 0, 3, 6, 9, and 24, and simulated intestinal juice with different four levels of pH Cont, 2, 3, and 7; antibiotic resistance: the effect of two strains, five levels of times, and types of antibiotics Cont, streptomycin, ampicillin, chloramphenicol, erythromycin, gentamycin, and kanamycin on growth rate and pH; adhesion with Caco2 cell: the effect of two strains, four levels of dilution of 2 strains Cont, 3, 4, and 5 adhesion of Caco 2 cell. Significance: a, P < 0,01; b: P< 0,001; c: P< 0,0001; d: nonsignificant. ∗ R2: determination coefficient, and CV: coefficient of variation. ∗SOV: source of variance.
Significance, means, and standard errors (SE) of factors affecting pH of KLDS 1.0727 and KLDS 1.0373 strains.
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| (S2) | (S1) | (S2) | (S1) | (S2) | (S1) |
|
| 4.59±0.23c | 4.45±0.20 | 4.92±0.10a | 4.90±0.10 | 5.33b ±0.06 | 5.32±0.06 |
|
| 0 | 33 | 0 | 33 | 0 | 24 |
|
| 5.56 ±0.05c | 3.70±0.01 | 5.81±0.02c | 4.11±0.07 | 5.74c ±0.01 | 4.55±0.14 |
|
| - | - | 2 | 0 | Chloramphenicol | Control |
|
| - | - | 5.21 ±0.10c | 4.60±0.16 | 5.72c ±0.01 | 4.97±0.14 |
|
| ||||||
|
| 99.96 | 99.85 | 99.92 | |||
|
| 0.5 | 0.73 | 0.4 | |||
See footnote of Table 2.
Significance, means, and standard errors (SE) of factors affecting survival or adhesion % of KLDS 1.0727 and KLDS 1.0373 strains.
|
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |
|
| (S2) | (S1) | (S1) | (S2) | (S2) | (S1) | (S2) | (S1) | (S1) | (S2) |
|
| 1.97±0.07b | 1.78±0.07 | 1.16±0.11b | 1.13±0.10 | 1.17±0.09c | 1.12±0.1 | 1.60±0.10c | 1.41±0.09 | 213±0.19d | 211±0.20 |
|
| 3 | 9 | 0 | 24 | 0 | 24 | 0 | 6 | ||
|
| 2.10±0.14c | 1.52±0.09 | 2.08±0.10c | 0.56±0.01 | 2.12±0.10c | 0.52±0.02 | 2.75±0.02c | 1.29±0.14 | ||
|
| 0.3 | 2 | 7 | 2 | 7 | 2 | Str. | Erth. | 3 | 5 |
|
| 2.17±0.09c | 1.66±0.09 | 1.38±0.16c | 0.94±0.09 | 1.34±0.14c | 0.96±0.09 | 2.36±0.14c | 0.83±0.09 | 268±0.15c | 148±0.12 |
|
| ||||||||||
|
| 86.6 | 99.71 | 99.64 | 96.48 | 0.78 | |||||
|
| 12.04 | 3.87 | 3.94 | 13.91 | 15.2 | |||||
See footnote of Table 2.
Figure 2Determining a standard curve for growth rate/hours and tolerant bile (0; 0.3; 1, 2%) with accumulated acid of KLDS 1.0727 and KLDS 1.0373 strains. (a) Growth rate and pH; (b) bile salts and pH.
Figure 3Resistance of KLDS 1.0727 and KLDS 1.0373 to different types of antibiotic as (OD)620 or pH. (amp), ampicillin; (chl), chloramphenicol; (cont), control; (erth), erythromycin; (gen), gentamicin; (kan), kanamycin; and (str), streptomycin.
Figure 4Tolerance of KLDS 1.0727 and KLDS 1.0373 to simulated intestinal juice (SIJ) with different pH under aerobic or anaerobic conditions.
Antibacterial activity of the KLDS 1.0727 and KLDS 1.0373 strains against foodborne pathogenic bacteria in terms of ZDI.
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
|
| 2.37±0.03 | +++ | 1.97± 0.03 | +++ | 2.17±0.09 | +++ | 2.20± 0.10 | +++ |
|
| 2.47±0.03 | +++ | 1.93±0.07 | +++ | 1.93±0.07 | +++ | 2.20± 0.10 | +++ |
|
| <.0001 | 0.4226 | 0.0198 | 0.0572 | ||||
|
| 1.000000 | 0.904762 | 0.978495 | 0.970588 | ||||
+++ refers to clear zone (14 mm, 3 points; 9–14 mm, 2 points; 1–9.9 mm, one point).
Figure 5
Figure 6Blood glucose mmol/dl and body weight/g of C57BL/6 mice with streptozotocin- (STZ-) induced diabetes during four weeks. (a) Average of blood glucose level, (b) body weight/g. (Cont), control; (STZ), streptozotocin; (INS+STZ), insulin; (S1), KLDS 1.0727; (S2), KLDS 1.0373.
Blood plasma assay (n=4, mean±SE).
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 0.45 -1.7 | 2.54±0.91 | 2.06±0.84 | 1.02±0.42 | 0.96±0.39 | 1.34±0.55 |
|
| 2.85 – 5.7 | 7.25±0.93b | 4.89±2.00bc | 3.38±1.38c | 3.46±1.41c | 3.44±1.40c |
|
| 0.93 – 1.81 | 4.20±0.90a | 1.55±0.63b | 2.26±0.92b | 2.39±0.98b | 2.22±0.91b |
|
| 2.07 – 3.63 | 1.14±0.47a | 0.83±0.34ab | 0.49±0.20b | 0.38±0.16b | 0.48±0.20b |
|
| 0.7-1.1 | 1.50±0.08 | 1.75±0.71 | 1.48±0.60 | 1.64±0.67 | 1.64±0.67 |
|
| 3.57 – 6.12 | 4.4±1.27bc | 4.40±1.80a | 9.4±2.71a | 3.1±0.89c | 5.1±1.47bc |
|
| ||||||
|
| ||||||
|
| ||||||
|
| 60.0-80.0 | 60.30±0.90 | 84.90±34.66 | 58.10±23.72 | 60.90±24.86 | 64.90±26.50 |
|
| 1.0 - 40.0 | 128.00±0.82 | 95.00±38.78 | 77.00±31.44 | 83.00±33.88 | 36.00±14.70 |
|
| 1.0 - 40.0 | 263.00±0.82 | 341.00±139.21 | 176.00±71.85 | 274.00±111.86 | 182.00±74.30 |
|
| 2.05±0.01b | 3.59±0.01ab | 2.29±0.01b | 3.30±1.35ab | 2.89±1.18b | |
|
| 0.01-20.0 | 8.50±0.90 | 4.90±2.00 | 3.90±1.59 | 2.60±1.06 | 3.90±1.59 |
|
| 35.0-55.0 | 34.50±0.90a | 39.10±15.96ab | 33.70±13.76ab | 36.50±14.90ab | 37.50±15.31ab |
|
| 25.0-40.0 | 25.80±0.90 | 45.80±18.70 | 24.40±9.96 | 24.40±9.96 | 27.40±11.19 |
|
| 1.5 -2.5 | 1.34±0.01a | 0.85±0.01ab | 1.38±0.01a | 1.50±0.61a | 1.37±0.56a |
|
| ||||||
|
| ||||||
|
| ||||||
|
| 1.07 – 7.14 | 8.60±3.51 | 10.50±4.29 | 8.00±3.27 | 11.80±4.82 | 10.80±4.41 |
|
| 53.0 – 132.0 | 44.30±18.09 | 40.50±16.53 | 39.10±15.96 | 37.40±15.27 | 41.90±17.11 |
|
| 142.0 –401.0 | 76.50±31.23b | 175.10±71.48ab | 180.60±73.73ab | 125.60±51.28ab | 164.90±67.32ab |
|
| ||||||
|
| ||||||
|
| ||||||
|
| 3-19 | 13.52±0.23 | 9.99± 0.36 | 10.60±0.21 | 11.13±0.28 | 10.93±0.20 |
TG, triglyceride; CHOL, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; GLU, glucose; Mg+2, magnesium; ALT, serum alanine aminotransferase; AST, aspartate aminotransferase; AST/ALT, presence of aspartate transaminase and serum alanine aminotransferase; TBA, total bile acid; ALB, albumin; GLUB, globulin; TP, total protein; BUN, uric nitrogen; CREA, creatinine; URIC, uric acid. (Cont), control; (STZ), streptozotocin; (INS+STZ), insulin; (S1), KLDS 1.0727; (S2), KLDS 1.0373.
Figure 7Histological examination of sacrifice mice organs (liver; pancreas; kidney, and spleen) streptozotocin-induced diabetes. (Cont), control; (STZ), streptozotocin; (INS+STZ), insulin; (S1), KLDS 1.0727, and (S2), KLDS 1.0373.
| Primer ID | Sequences (5′ → 3′ | Reference |
| Lb-PTC-F | GCCAGAAACGCTCAAGAT | [ |
| Lb-PTC-R | GGCTTCGTATAAGCCATACC | |
| Lb-OTC-F | GTGAAAGCAACTGGGAAGA | |
| Lb-OTC-R | GTTATGGAAAGCAGGCAAAC | |
| Lb-TDC-F | CGATCAAGCAGAGTCCATTAC | |
| Lb-TDC-R | CGGCACCCTTCTCAAATAC |